Type 2 diabetes is one of the fastest growing diseases in Canada, with approximately 60,000 new patients diagnosed each year. In recent years, there have been major advancements in the treatment of type 2 diabetes with the discovery of new drug classes, such as the sodium-glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors have become increasingly popular, as they effectively lower blood sugar levels without the side effects of other antidiabetic drugs. However, these drugs have been associated with frequent urinary tract infections, and there are signals from trials that they may be associated with an increased risk of bladder cancer. To date, however, no study has been conducted in the real-world setting to assess this association. Thus, to address this gap in knowledge, I will conduct a multicenter cohort study among patients with type 2 diabetes using data sources from Canada, Europe and the Middle East. As a possible association may be explained by increased screening of the urinary tract, this international study will be specifically designed to differentiate between a possible biological effect and detection bias. Thus, this study will provide much needed information on the safety of SGLT2 inhibitors, and will be of value to regulatory agencies, physicians, and patients.